DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Entinostat is an investigational drug.
There have been 62 clinical trials for Entinostat. The most recent clinical trial was a Phase 2 trial, which was initiated on May 15th 2018.
The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Lung Neoplasms. The leading clinical trial sponsors are Syndax Pharmaceuticals, National Cancer Institute (NCI), and Merck Sharp & Dohme Corp.
There are one hundred and forty-five US patents protecting this investigational drug and one international patent.
Recent Clinical Trials for Entinostat
|Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer||UNC Lineberger Comprehensive Cancer Center||Phase 2|
|Molibresib and Entinostat in Treating Patients With Advanced or Refractory Solid Tumors or Lymphomas||National Cancer Institute (NCI)||Phase 1|
|Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers||AstraZeneca||Phase 1/Phase 2|
Top disease conditions for Entinostat
Top clinical trial sponsors for Entinostat
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Entinostat||See Pricing||Heat shock protein 70 (hsp-70) receptor ligands||Duke University (Durham, NC)||See Pricing|
|Entinostat||See Pricing||Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: III||Frequency Therapeutics, Inc. (Woburn, MA)||See Pricing|
|Entinostat||See Pricing||Liposomal compositions of epoxyketone-based proteasome inhibitors||Onyx Therapeutics, Inc. (Thousand Oaks, CA)||See Pricing|
|Entinostat||See Pricing||Oxabicycloheptanes and oxabicycloheptenes, their preparation and use||Lixte Biotechnology, Inc. (East Setauket, NY)||See Pricing|
|Entinostat||See Pricing||Substituted 6-aminopurines for targeting HSP90||Duke University (Durham, NC)||See Pricing|
|Entinostat||See Pricing||Cyclodextrin complexation methods for formulating peptide proteasome inhibitors||Onyx Therapeutics, Inc. (Thousand Oaks, CA)||See Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Entinostat||World Intellectual Property Organization (WIPO)||2015148714||2034-03-25||See Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|